A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
A phase 1/2 trial of Tislelizumab in advanced solid tumours, run by FindCure Biosciences (ZhongShan) Co., Ltd., now recruiting.
Overview
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT06499350 by FindCure Biosciences (ZhongShan) Co., Ltd., with 33 participants planned, started 2024-11-13 and due to reach its primary completion in 2026-12-01. Interventions recorded: FC084CSA+Tislelizumab combination (dose escalation) and RP2D of FC084CSA+Tislelizumab combination (dose expansion).
Similar pages
not linked directly; found by shared links- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SKB518 in Patients With Lung Cancer
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.